Compare Recursion Pharmaceuticals Inc (RXRX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs VNET Group Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while VNET Group Inc trades at $6.53 (market cap $1.86B). The key difference: Recursion Pharmaceuticals Inc and VNET Group Inc are close in size by market cap. Which is the better fit depends on your goals.
| RXRX | VNET | |
|---|---|---|
Market Cap | $1.74B | $1.86B |
Sector | Health | Technology |
52-Week High | $6.79 | $14.03 |
52-Week Low | $2.84 | $6.06 |
Enterprise Value | $1.26B | $5.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
VNET trades at $6.75, up 5.97% today, amid a bearish technical signal. The company reported Q2 2026 revenue growth driven by wholesale data center demand but missed EPS estimates, with a net loss of $256.77 million in 2025. Analyst consensus is 62.5% buy, though a class action settlement and rising leverage pose risks.
Outlook is mixed: strategic cooperation with CATL and secured capacity support growth, but negative margins, high debt, and cash flow concerns challenge profitability. Investors face upside from AI infrastructure demand against balance sheet and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
